Handbook of Disease Burdens and Quality of Life Measures pp 4240-4240 | Cite as
International Prognostic Scoring System
Despite the multitude of methods developed to evaluate the potential clinical outcome in patients with myelodysplastic syndromes, in 1997 an International Risk Analysis Workshop was convened to establish a consensus prognostic risk-based analysis system. The evaluation of disease risk and outcome in patients with myelodysplastic syndromes is critical to the application of adequate treatment strategies. The International Prognostic Scoring System (IPSS), which is based on the percentage of bone marrow blasts, karyotype and the number of cytopenias, predicts both survival and risk of progression to acute myelogenous leukemia, and should help identify patients who might benefit from therapeutic treatment.